(Q33796176)

English

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

29 July 2017

Randomized, phase III trial of first-line figitumumab in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin alone in patients with advanced non-small-cell lung cancer (English)

1 reference

Europe PubMed Central

29 July 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Maciej Krzakowski

4

object named as

Maciej Krzakowski

1 reference

Europe PubMed Central

29 July 2017

10

object named as

Jacek Jassem

1 reference

Europe PubMed Central

29 July 2017

object named as

Tony Mok

6

1 reference

ORCID Public Data File 2021

2

object named as

Silvia Novello

1 reference

Europe PubMed Central

29 July 2017

1

object named as

Corey J Langer

1 reference

Europe PubMed Central

29 July 2017

author name string

Keunchil Park

3

1 reference

Europe PubMed Central

29 July 2017

Daniel D Karp

5

1 reference

Europe PubMed Central

29 July 2017

Rebecca J Benner

7

1 reference

Europe PubMed Central

29 July 2017

Judith R Scranton

8

1 reference

Europe PubMed Central

29 July 2017

Anthony J Olszanski

9

1 reference

Europe PubMed Central

29 July 2017

language of work or name

0 references

publication date

2 June 2014

1 reference

Europe PubMed Central

29 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

29 July 2017

32

1 reference

Europe PubMed Central

29 July 2017

2059-2066

1 reference

Europe PubMed Central

29 July 2017

19

1 reference

Europe PubMed Central

29 July 2017

Phase 1 study of ganitumab (AMG 479), a fully human monoclonal antibody against the insulin-like growth factor receptor type I (IGF1R), in Japanese patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

4 July 2018

Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

4 July 2018

Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

4 July 2018

Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

4 July 2018

Targeting insulin and insulin-like growth factor signalling in oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

4 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

4 July 2018

Expression and function of the insulin-like growth factor I system in human non-small-cell lung cancer and normal lung cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

4 July 2018

Retraction. “Phase II study of the anti–insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer”.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

30 October 2018

Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

30 October 2018

Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4067944

30 October 2018

Expression of insulin-like growth factor receptors I and II in normal human lung and in lung cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/24888810

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1200/JCO.2008.19.9331

Identifiers

10.1200/JCO.2013.54.4932

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

1 reference

Europe PubMed Central

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33796176&oldid=2041924132"